Topical Tips: Experts on AhR Activation for Treating Psoriasis (CME/CE Monograph)
Activity Description and Purpose
Established topical therapies for psoriasis have a variety of drawbacks that impact patient adherence, satisfaction, and overall effectiveness. Two newer nonsteroidal topical agents approved by the US Food and Drug Administration have overcome many of the limitations of older topical therapies. One agent’s mechanism of action (phosphodiesterase-4 inhibition) is familiar in dermatology, but the other (aryl hydrocarbon receptor activation) is a novel mechanism. This educational activity is intended to focus on practical management tips for using the aryl hydrocarbon receptor activation agent to optimize patient outcomes as well as to provide an overview of relevant clinical data for these agents.
This educational activity is intended for dermatologists and dermatology advanced practice providers, including nurses, nurse practitioners, and physician assistants.
After completing this activity, participants will be better able to:
- Describe the mechanism of action of aryl hydrocarbon receptor agonism in the treatment of plaque psoriasis
- Review evidence on the clinical efficacy and safety of aryl hydrocarbon receptor treatment for plaque psoriasis
- Develop appropriate education and counseling strategies to achieve improved outcomes with the use of aryl hydrocarbon receptor agonism in the treatment of plaque psoriasis
Michael Cameron, MD
Alexandra K. Golant, MD
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Michael Cameron, MD, is a consultant for AbbVie Inc, Arcutis Biotherapeutics, Inc, Bristol-Myers Squibb Company, Dermavant Sciences, Inc, Eli Lilly and Company, Evelo Biosciences, Inc, Incyte, and Janssen Pharmaceuticals, Inc; and is on the speakers bureau for AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Dermavant Sciences, Inc, Eli Lilly and Company, Incyte, Journey Medical Corporation, LEO Pharma, Ortho Pharmaceutical, Regeneron Pharmaceuticals, Inc, and Sanofi.
Alexandra K. Golant, MD, is a consultant for AbbVie Inc, Amgen Inc, Arcutis Biotherapeutics, Inc, Dermavant Sciences, Inc, Eli Lilly and Company, Evelo Biosciences, Incyte, Janssen Pharmaceuticals, Inc, LEO Pharma, Regeneron Pharmaceuticals, Inc, and Sanofi; and is on the speakers bureau for AbbVie Inc, Arcutis Biotherapeutics, Inc, Dermavant Sciences, Inc, Eli Lilly and Company, Incyte, Regeneron Pharmaceuticals, Inc, and Sanofi.
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Medical Writer: Cheryl Guttman Krader has individual stocks in Johnson & Johnson Vision Care, Inc.
Other MedEdicus planners and managers have no relevant commercial relationships to disclose.
Learners must take the pretest, read the monograph, and complete the posttest and evaluation form to receive a certificate of completion. You must complete the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dermavant Sciences, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco, or Dermavant Sciences, Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 297
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation